Advice
Following a full submission.
Paricalcitol (Zemplar) is not recommended for use within NHS Scotland for the prevention and treatment of secondary hyperparathyroidism in patients with chronic renal failure undergoing haemodialysis.
The benefits and adverse effects of paricalcitol are similar to another vitamin D analogue with which it has been compared. The economic case has not been demonstrated.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- paricalcitol 5mcg/ml and 10mcg/2ml solution for Injection (Zemplar)
- SMC ID:
- 288/06
- Indication:
- Prevention and treatment of secondary hyperparathyroidism in patients with chronic renal failure undergoing haemodialysis
- Pharmaceutical company
- Abbott Laboratories
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 August 2006